A grey-market pre-mixed blend of CJC-1295 (no DAC / Modified GRF 1-29), a GHRH analog, and Ipamorelin, a selective ghrelin-receptor agonist. The blend itself is NOT clinically validated — no controlled human trial has tested this specific combination. The pharmacological rationale (GHRH + GHRP synergy for pulsatile GH amplification) is inferred from studies of other GHRH/GHRP pairs.
Mechanism of Action
CJC-1295 (no DAC / Modified GRF 1-29) binds the pituitary GHRH receptor to stimulate GH release, while Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that does not meaningfully elevate cortisol or prolactin. Any additive or synergistic GH response in humans is extrapolated from studies of other GHRH + GHRP combinations; it has not been directly demonstrated for this specific blend.
Research Summary
Each component is characterized in isolation, but no published human trial has tested the CJC-1295 (no DAC) + Ipamorelin combination. The "no DAC" specification distinguishes Modified GRF 1-29 (half-life ~30 min, pulsatile) from CJC-1295 with DAC (albumin-bound, multi-day half-life) — these are pharmacokinetically distinct molecules and should not be conflated. The often-cited Teichman 2006 JCEM trial studied CJC-1295 WITH DAC, not the no-DAC form and not a combination with Ipamorelin.
Verified testing for CJC-1295/Ipamorelin
Aggregated from 78 lab-verified Certificates of Analysis uploaded directly by 2 verified labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
Scored vendors carrying CJC-1295/Ipamorelin, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. PMID 19240251. https://pubmed.ncbi.nlm.nih.gov/19240251/
Frequently asked questions
Has CJC-1295/Ipamorelin been independently lab-tested?
Disclosed Labs has collected 78 Certificates of Analysis (COA) for CJC-1295/Ipamorelin from 13 independent testing labs. 34 vendors have submitted material for testing. Products average 99.7% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/cjc-1295-ipamorelin/testing.
What is the average purity of CJC-1295/Ipamorelin on the market?
Based on 78 COAs analyzed by Disclosed Labs, CJC-1295/Ipamorelin products average 99.7% (±0.3%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/cjc-1295-ipamorelin/coas.
Which labs have tested CJC-1295/Ipamorelin?
Independent labs that have tested CJC-1295/Ipamorelin include: ILS Labs (Grade A), Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.
Where can researchers source CJC-1295/Ipamorelin?
8 vendors with Disclosed Labs trust grades currently list CJC-1295/Ipamorelin, including Glacier Aminos, Ion Peptide, Peptide Partners. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/cjc-1295-ipamorelin.
How does CJC-1295/Ipamorelin work?
CJC-1295 (no DAC / Modified GRF 1-29) binds the pituitary GHRH receptor to stimulate GH release, while Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that does not meaningfully elevate cortisol or prolactin. Any additive or synergistic GH response in humans is extrapolated from studies of other GHRH + GHRP combinations; it has not been directly demonstrated for this specific blend.
What does the research say about CJC-1295/Ipamorelin?
Each component is characterized in isolation, but no published human trial has tested the CJC-1295 (no DAC) + Ipamorelin combination. The "no DAC" specification distinguishes Modified GRF 1-29 (half-life ~30 min, pulsatile) from CJC-1295 with DAC (albumin-bound, multi-day half-life) — these are pharmacokinetically distinct molecules and should not be conflated. The often-cited Teichman 2006 JCEM trial studied CJC-1295 WITH DAC, not the no-DAC form and not a combination with Ipamorelin.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs